Martin H. Kroll

Martin H. Kroll

Auto-generated profile, based on publicly available information

Martin H. Kroll

Analytics and Statistical Applications, Quest Diagnostics, Secaucus, New Jersey, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in Clinical Biochemistry
Verified
Journal Article
Closed access
PSPornpen Srisawasdi
Pornpen Srisawasdi
SVSomlak Vanavanan
Somlak Vanavanan
MRMana Rochanawutanon
Mana Rochanawutanon
KKKhanat Kruthkul
Khanat Kruthkul
KKKazuhiko Kotani
Kazuhiko Kotani
MKMartin H. Kroll
Martin H. Kroll

1 January 2015 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
SVSomlak Vanavanan
Somlak Vanavanan
PSPornpen Srisawasdi
Pornpen Srisawasdi
MRMana Rochanawutanon
Mana Rochanawutanon
JKJirapa Kerdmongkol
Jirapa Kerdmongkol
MKMartin H. Kroll
Martin H. Kroll
Small, dense low-density lipoprotein cholesterol (sdLDL-C) has been linked to the progression of cardiovascular disease. We compared two methods for determination of sdLDL-C, a direct enzymatic (ENZ) method and a polyacrylamide tube gel electrophoresis (PGE) assay, and investigated the associations of both sdLDL-C measurements with metabolic syndrome. We analyzed 242 patient sera for sdLDL and atherosclerosis-related markers. The PGE method separates the intermediate-density lipoprotein particles into three midbands (MID-A to MID-C) and the LDL particles into seven subfractions (LDL1 to LDL7); the sdLDL-PGE result is calculated as the sum of cholesterol concentrations from LDL3 to LDL7. The regression equation for sdLDL-C was [ENZmmol/L]=0.779[PGE]+0.67, r=0.713. ENZ showed higher sdLDL-C concentrations than PGE (0.86±0.33 vs. 0.24±0.32 mmol/L); however, the difference was not associated with sdLDL-C concentration (p=0.290). sdLDL-C, as measured with the enzymatic assay, exhibited significant positive correlations with very-low-density lipoprotein, MID-C, MID-B, and LDL2 (all p0.600). The ENZ and PGE methods yielded similar patterns of correlation between sdLDL-C, and atherosclerosis-related markers. Using logistic regression, sdLDL-ENZ and apolipoprotein B were identified as significant predictors of metabolic syndrome (p<0.03). The ENZ assay for sdLDL-C correlated well with the PGE method. The ENZ method measures a broader range of atherogenic lipoprotein particles than PGE and has the potential to identify subjects with vascular risk, thus contributing in directing specific interventions for cardiovascular prevention.

1 October 2012 in Clinica Chimica Acta
Verified
Journal Article
Closed access
JTJosenia N.M. Tan
Josenia N.M. Tan
MKMartin H. Kroll
Martin H. Kroll
COCarl J. O'HAra
Carl J. O'HAra
PEPeter C. Everett
Peter C. Everett
EEEvrim Erdogan
Evrim Erdogan

4 June 2024 in Microbiology Spectrum
Verified
Journal Article
Open access
HKHema Kapoor
Hema Kapoor
CBCaixia Bi
Caixia Bi
MKMartin H. Kroll
Martin H. Kroll
ASAnn Elizabeth Salm
Ann Elizabeth Salm
EDEdward A. Dominguez
Edward A. Dominguez
Transplant patients are at risk of infections due to long-term immunosuppression contributing to morbidity and mortality in this population. Post-transplant testing guidelines were established to monitor and guide therapeutic interventions in transplant recipients. We hypothesize that there are gaps in adherence to the recommended frequency of laboratory testing in post-transplant patients. We analyzed national reference laboratory data to compare viral post-transplant infection (PTI) testing frequency with their respective published guidelines to understand patient uptake and compliance. We evaluated the ordering patterns, positivity rates, and frequency of molecular infectious disease tests (MIDTs). We included 345 patients with International Classification of Diseases (ICD)-10 codes for transplant (Z940-Z942, Z944, Z9481, Z9483, Z9484) with at least two tests (within 7 days) in January 2019 and at least one test in December 2020 to find patients in the post-transplant period. We analyzed two cohorts: kidney transplant recipients (KTRs; 40%) and non-KTR (60%) then followed them longitudinally for the study period. In KTR cohort, high-to-low proportion of ordered MIDT was blood BK virus (bBKV) followed by cytomegalovirus (CMV); in non-KTR cohort, CMV was followed by Epstein–Barr virus (EBV). KTR cohort positivity was highest for urine BK virus (uBKV; 58%) followed by EBV (46%), bBKV (40%), and CMV (31%). Non-KTR cohort positivity was highest for uBKV (64%), EBV (51%), CMV (30%), bBKV (8%), and adenovirus (7%). All patients were tested at progressively longer intervals from the date of the first post-transplant ICD-10-coded test. More than 40% of the KTR cohort were tested less frequently for EBV and bBKV, and more than 20% of the non-KTR cohort were tested for EBV less frequently than published guidelines 4 months after transplant. Despite regular testing, the results of MIDT testing for KTR and non-KTR patients in the post-transplant period are not aligned with published guidelines. IMPORTANCE: Guidance for post-transplant infectious disease testing is established, however, for certain infections it allows for clinician discretion. This leads to transplant center policies developing their own testing/surveillance strategies based on their specific transplant patient population (kidney, stem cell, etc.). The Organ Procurement and Transplant Network (OPTN) has developed a strategic plan to improve and standardize the transplant process in the US to improve outcomes of living donors and recipients. Publishing national reference lab data on the testing frequency and its alignment with the recommended guidelines for post-transplant infectious diseases can inform patient uptake and compliance for these strategic OPTN efforts.